Logomix is a biotechnology company that specializes in medication research, cell therapy, and clinical trials.
Logomix has raised $18.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in July 2025.
Logomix's investors include Mitsubishi UFJ Capital, UTokyo Innovation Platform, Angel Bridge, ITOCHU Technology Ventures, JAFCO.
Logomix is headquartered in Harumi, Japan.
Logomix is a biotechnology company that specializes in medication research, cell therapy, and clinical trials.
Logomix is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Logomix — Funding & Investors." VCBacked, July 30, 2025, https://www.vcbacked.co/company/logomix. Accessed September 30, 2026.
VCBacked. (2025). Logomix — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/logomix
{{cite web |title=Logomix — Funding & Investors |url=https://www.vcbacked.co/company/logomix |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated